Insmed Incorporated (NASDAQ:INSM) on May 13, 2014 announces that multiple posterpresentations reporting data on ARIKAYCE(TM), or liposomal amakacinfor inhalation, for the treatment of Pseudomonas aeruginosainfections in cystic fibrosis (CF) patients and for the treatment ofpatients with treatment-resistant nontuberculous mycobacterial (NTM)lung infections will be presented at the American Thoracic SocietyAnnual Meeting 2014, taking place May 16-21 in San Diego, California. Insmed Incorporated (NASDAQ:INSM) stock performance was … Continue reading Biotech Decliners: Insmed Incorporated (NASDAQ:INSM), 22nd Century Group Inc (NYSEMKT:XXII), Concert Pharmaceuticals Inc (NYSE:JMPC), Relypsa Inc (NASDAQ:RLYP)